Gracell Biotechnologies

Gracell Biotechnologies, Inc. engages in the research and development activities of biotechnological and pharmaceutical industries. The firm through its FasTCAR and TruUCAR platforms, it is developing a pipeline of autologous and allogeneic cell therapy candidates with the potential to treat both hematologic malignancies and solid tumors. The company was founded by William Wei Cao in 2017 and is headquartered in Suzhou, China.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Gracell Biotechnologies reports solid financials and advances lead CAR-T therapy

Gracell Biotechnologies showcased strong financials and promising progress with their lead CAR-T therapy GC012F for multiple myeloma.
While facing challenges in trial optimization and enrollment, the company is well-positioned to leverage partnerships and drive future growth.
Opportunities lie in expanding partnerships, generating durability data, and prioritizing pipeline development to enhance market competitiveness and patient outcomes.

Gracell Biotechnologies reports Q1 loss, advances CAR-T therapy pipeline

Gracell Biotechnologies faces financial challenges with a net loss in Q1 2023 but maintains a strong cash position for future operations.
The company's focus on advancing CAR-T therapy, particularly GC012F, and venturing into autoimmune disease clinical development highlight strategic growth initiatives.

Gracell Biotechnologies excels in Q2 with promising trial results and funding success

Gracell Biotechnologies showcased strong performance in Q2 2023 with positive trial results and successful fundraising, underlining their commitment to innovation and growth.
While facing challenges in communication and sustaining trial outcomes, the company's strategic strengths and opportunities position them for future success in the biotech sector.
Investors should take note of Gracell's progress in advancing novel therapies like GC012F and their financial stability, signaling potential for long-term value creation.

Gracell Biotechnologies reports strong Q3 performance and advances CAR-T therapies

Gracell Biotechnologies reported positive financial performance and strong clinical data, positioning the company well for future growth and innovation.
While facing challenges such as limited information availability and regulatory complexities, the company remains focused on advancing its CAR-T therapies and addressing unmet medical needs.
Opportunities lie in leveraging financial strength to attract partners, showcasing research at industry events, and advancing clinical programs for myeloma and autoimmune diseases.
Overall, Gracell Biotechnologies' emphasis on safety, efficacy, and innovation underscores its commitment to developing transformative therapies for patients in need.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Samuel Zhang, Ph.D.

Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer

Gracell also presented data on GC012F for treatment of B-NHL and allogeneic TruUCAR-candidate GC502 for treatment of B-ALL Management to host clinical update call on Monday, June 13, at 8:00AM ET SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , June 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the updated clinical data from a multicenter study evaluating GC012F, the Company's autologous CAR-T therapeutic candidate dual-targeting B-cell maturation antigen (BCMA) and CD19, for the treatment of relapsed/refractory multiple myeloma (RRMM).

Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , June.

Gracell Biotechnologies Schedules Clinical Update Call After EHA2022

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , May 26, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will present updated clinical data from a multicenter investigator-initiated trial (IIT) evaluating GC012F, the company's B-cell maturation antigen (BCMA) and CD19 dual-targeting CAR-T candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM) in an oral abstract presentation at the 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting.

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Dr. William Cao - Founder, Chairman, and CEO Dr. Martina Sersch - CMO Dr. Kevin Xie - CFO Conference Call Participants Joe Catanzaro - Piper Sandler Kelly Shi - Jefferies Nick Abbott - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. Welcome to the Gracell Biotechnologies First Quarter 2022 Conference Call.

Gracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q1 2022 Results - Earnings Call Transcript

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, May 16, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or “Company”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported first quarter unaudited financial results for the three months ended March 31, 2022, and provided corporate updates.

Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of three abstracts that it will present at the European Hematology Association 2022 Hybrid Congress (EHA2022 Congress), being held from June 9 – June 12 in Vienna, Austria.

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in May 2022 as follows:

Gracell Biotechnologies to Participate in Three Investor Conferences in May

SAN DIEGO, Calif., and SUZHOU, China, May 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the first quarter ended March 31, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, May 16, 2022. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO, Calif. and SUZHOU, China , April 28, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of its oral abstract presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held from June 3-7 in Chicago, Illinois.

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

SAN DIEGO, Calif. and SUZHOU, China, April 22, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2022.

Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021

PALO ALTO, Calif. and SUZHOU, China , April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its abstract providing the follow-up clinical data of GC012F in the treatment of relapsed/refractory multiple myeloma (RRMM) has been selected for oral presentation as part of an Oral Abstract Session at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting

Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China , April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL

PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in April 2022 as follows:

Gracell Biotechnologies to Participate in Three Investor Conferences in April

Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2021 Results - Earnings Call Transcript

PALO ALTO, Calif. and SUZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported fourth quarter and full year unaudited financial results for the period ended December 31, 2021, and provided corporate updates.

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 32nd Annual Healthcare Conference from March 15th to 17th.

Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference

Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ( "Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held from April 8-13 in New Orleans, Louisiana.

Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022

PALO ALTO, Calif. and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on Monday, March 14, 2022. The management team will host a live audio webcast and conference call at 8:00AM Eastern Time.

Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022

SUZHOU, China, and PALO ALTO, Calif., Feb. 22, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced multiple advancements of its TruUCAR platform, the Company's proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered "off-the-shelf" as stand-alone therapy at lower cost and with greater convenience.

Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has dosed multiple patients in a clinical trial evaluating GC012F, the Company's autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19 in B-cell non-Hodgkin's lymphoma (B-NHL).

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Citi 2022 Immuno-Oncology Summit on February 16th.

Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27th to 28th.

Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

SUZHOU, China and PALO ALTO, Calif. , Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its newly established research facility, the Innovation Center, is scheduled to open in San Diego, California, during the first quarter of 2022.

Gracell Biotechnologies Unveils Innovation Center in U.S.

iShares Nasdaq Biotechnology ETF

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).

News for Gracell Biotechnologies Stock (GRCL)